Actinium-225 (225Ac) is
an excellent candidate for targeted
radiotherapeutic applications for treating cancer, because of its
10-day half-life and emission of four high-energy α2+ particles. To harness and direct the energetic potential of actinium,
strongly binding chelators that remain stable in vivo during biological targeting must be developed. Unfortunately, controlling
chelation for actinium remains challenging. Actinium is the largest
+3 cation on the periodic table and has a 6d05f0 electronic configuration, and its chemistry is relatively unexplored.
Herein, we present theoretical work focused on improving the understanding
of actinium bonding with macrocyclic chelating agents as a function
of (1) macrocycle ring size, (2) the number and identity of metal
binding functional groups, and (3) the length of the tether linking
the metal binding functional group to the macrocyclic backbone. Actinium
binding by these chelators is presented within the context of complexation
with DOTA4–, the most relevant Ac3+ binding
agent for contemporary radiopharmaceutical applications. The results
enabled us to develop a new strategy for actinium chelator design.
The approach is rooted in our identification that Ac3+–chelation
chemistry is dominated by ionic bonding interactions and relies on
(1) maximizing electrostatic interactions between the metal binding
functional group and the Ac3+ cation and (2) minimizing
electronic repulsion between negatively charged actinium binding functional
groups. This insight will provide a foundation for future innovation
in developing the next generation of multifunctional actinium chelators.